Patents Assigned to Stichting Rega VZW (REGA)
-
Publication number: 20070031409Abstract: A method for producing biologically active Fv antibody fragments that have a neutralizing effect on the anti-viral activity of human interferon-gamma (IFN-?) by inserting an isolated nucleic acid, having nucleotide sequences that encode the VH and VL domains of the D9D10 monoclonal antibody and a nucleotide sequence that encodes a linker peptide which links the VH and VL domains, into a suitable expression vector, in order to encode FV antibody fragments. Such Fv antibody fragments can be used to treat human diseases, such as endotoxic shock, local inflammation, cerebral malaria, and autoimmune arthritis.Type: ApplicationFiled: February 11, 2005Publication date: February 8, 2007Applicant: Stichting Rega VZWInventors: Alfons Billiau, Guido Froyen
-
Patent number: 5840524Abstract: This invention is directed to a new family of mammalian chemokine proteins, which have been designated granulocyte chemotactic protein-2 (GCP-2) proteins, and includes mammalian GCP-2, sequence-related variants of mammalian GCP-2, and distinct peptide fragments of GCP-2.Type: GrantFiled: May 24, 1995Date of Patent: November 24, 1998Assignee: Stichting Rega vzwInventors: Jo Van Damme, Paul Proost
-
Patent number: 5668113Abstract: It has been found that 1,5-anhydrohexitol nucleoside analogues, wherein a 4-substituted-2,3,4-trideoxy-1,5-anhydrohexitol is coupled via its 2-position to the heterocyclic ring of a pyrimidine or purine base, exhibit remarkable anti-viral properties against herpes viruses, pox viruses and related viruses.The new nucleoside analogues are represented by the general formula I ##STR1## wherein B is a heterocyclic ring derived from a pyrimidine or purine base, X represents H, N.sub.3, F, Cl, Br, I, amino, --NHR.sup.2, --N(R.sup.2).sub.2, --OR.sup.2, --SR.sup.2 or CN, R.sup.1 and R.sup.2 are the same or different and hydrogen, alkyl, acyl or phosphate groups are represented, or wherein X is hydrogen and a double bond is situated between the 3- and 4- position of the 1,5-anhydrohexitol ring.Pharmaceutically acceptable salts and esters thereof are included.Type: GrantFiled: June 7, 1995Date of Patent: September 16, 1997Assignee: Stichting Rega VZWInventors: Erik Desire Alice De Clercq, Piet Andre Maurits Herdewlin, Arthur Albert Edgard Van Aerschot
-
Patent number: 5607922Abstract: 1,5-Anhydrohexitol nucleoside analogues represented by the general formula I: ##STR1## wherein the hexitol has the D-configuration and the carbon atom on which the base moiety and the X substituent stand both have the (S)-configuration and further wherein:B is a heterocyclic ring selected from the group consisting of pyrimidine and purine bases; andX is hydrogen, azido, F, Cl, Br, I, amino, --NHR.sup.2, --N(R.sup.2).sub.2, --OR.sup.2, --SR.sup.2, or CN; wherein R.sup.1 and R.sup.2 are the same or different and are selected from the group consisting of hydrogen, substituted or unsubstituted C.sub.1 -C.sub.20 alkyl, substituted or unsubstituted C.sub.1 -C.sub.20 alkenyl, aroyl, C.sub.1 -C.sub.20 alkanoyl, and phosphoryl.These nucleoside analogues are useful as antiviral agents against herpes simplex virus, vaccina virus, or varicella zoster virus. The definition of the X group should include --N(R.sup.2).sub.2 instead of --N(N.sup.2).sub.2.Type: GrantFiled: December 17, 1993Date of Patent: March 4, 1997Assignee: Stichting Rega VZWInventors: Erik D. A. De Clercq, Piet A. M. Herdewijn, Arthur A. E. Van Aerschot
-
Patent number: 5292505Abstract: Sulphated vinyl polymers such as sulphated polyvinylalcohol, sulphated copolymers of (meth)acrylic acid and vinylalcohol, and pharmaceutically acceptable salts thereof, have an antiviral effect against human immunodeficiency virus and may therefore be used as a therapeutic agent for treating retrovirus infections like AIDS and AIDS-related diseases. Their antiviral activity is apparently based on inhibition of virus adsorption; their inhibitory effect on giant cell formation is stronger than that of dextran sulphate.Type: GrantFiled: January 15, 1992Date of Patent: March 8, 1994Assignees: Stichting Rega VZW, Richter Gedeon Vegyeszeti Gyar RTInventors: Masanori Baba, Erik D. A. De Clercq, Sandor Gorog, Miklos Low, Miklos Nagy, Sandorne Gyorgyi
-
Patent number: 5152978Abstract: Sulphated vinyl polymers such as sulphated polyvinylalcohol, sulphated copolymers of (meth)acrylic acid and vinylalcohol, and pharmaceutically acceptable salts thereof, have an antiviral effect against human immunodeficiency virus and may therefore be used as a therapeutic agent for treating retrovirus infections like AIDS and AIDS-related diseases. Their antiviral activity is apparently based on inhibition of virus adsorption; their inhibitory effect on giant cell formation is stronger than that of dextran sulphate.Type: GrantFiled: February 23, 1989Date of Patent: October 6, 1992Assignees: Stichting Rega VZW, Richter Gedeon Vegyeszeti Gyar R.T.Inventors: Masanori Baba, Erik D. A. De Clercq, Sandor Gorog, Miklos Low, Miklos Nagy, Sandorne Gyorgyi
-
Patent number: 5137724Abstract: The antiviral activity of 5-fluoro-uracil, 5-fluoro-2'-deoxyuridine and similar thymilydate synthetase inhibitors towards herpes viruses can be potentiated dramatically by combining these compounds with compounds having viral thymidine kinase inhibiting activity.Type: GrantFiled: July 22, 1991Date of Patent: August 11, 1992Assignee: Stichting Rega VZWInventors: Jan M. R. Balzarini, Erik D. A. De Clercq
-
Patent number: 5116822Abstract: The compound 2',3'-dideoxycytidinene has an antiviral effect against human immunodeficiency virus (HIV) and may therefore be used as a therapeutic agent for treating AIDS and related diseases.Type: GrantFiled: July 2, 1990Date of Patent: May 26, 1992Assignees: Stichting Rega VZW, The United States of America as represented by the Department of Health and Human SericesInventors: Erik D. A. De Clercq, Piet A. M. M. Herdewijn, Samuel Broder, Jan M. R. Balzarini
-
Patent number: 4988678Abstract: The antitumor activity of 5-fluorouracil and its precursors against adenocarcinomas can be potentiated without a corresponding increase in toxicity by combining these compounds with (E)-5-(2-bromovinyl)-uracil or a precursor thereof. The combinations may have the form of a single composition or two separate compositions.Type: GrantFiled: June 29, 1989Date of Patent: January 29, 1991Assignee: Stichting Rega VZWInventors: Erik De Clercq, Masaaki Iigo
-
Patent number: 4963533Abstract: The present invention relates to a composition containing the compound 2', 3'-dideoxycytidinene which has an antiviral effect against human immunodeficiency virus (HIV) and may therefore be used as a therapeutic agent for the treatment of AIDS and AIDS related diseases.Type: GrantFiled: October 24, 1986Date of Patent: October 16, 1990Assignees: Stichting Rega VZW (REGA), The Government of the United States of AmericaInventors: Erik D. A. de Clercq, Piet A. M. M. Herdewijn, Samuel Broder, Jan M. R. Balzarini
-
Patent number: 4894365Abstract: The antitumor activity of 5-fluorouracil and its precursors against adenocarcinomas can be potentiated without a corresponding increase in toxicity by combining these compounds with (E)-5-(2-bromovinyl)-uracil or a precursor thereof. The combinations may have the form of a single composition or two separate compositions.Type: GrantFiled: February 11, 1988Date of Patent: January 16, 1990Assignee: Stichting Rega VZWInventors: Erik De Clercq, Masaaki Iigo
-
Patent number: 4724233Abstract: The (S) and (RS) forms of certain phosphonylmethoxyalkyl adenines and their salts have an antiviral effect against several DNA viruses and can be used for the treatment of virus diseases in human and veterinary medicine.Type: GrantFiled: April 21, 1986Date of Patent: February 9, 1988Assignees: Stichting Rega VZW, Ceskoslovenska Akademie VEDInventors: Erik De Clercq, Antonin Holy, Ivan Rosenberg
-
Patent number: 4605658Abstract: Certain esters of 3-(adenin-9-yl)-2-hydroxypropanoic acid are disclosed which exhibit an improved broad spectrum antiviral activity while having a low toxicity for living cells. They can be used for treatment of virus diseases in human and veterinary practice.Type: GrantFiled: October 5, 1984Date of Patent: August 12, 1986Assignees: Ceskoslovenska Akademie Ved., Stichting Rega VZWInventors: Antonin Holy, Erik de Clercq